142 related articles for article (PubMed ID: 10624460)
1. Poor glycemic control impairs the response of biochemical parameters of bone formation and resorption to exogenous 1,25-dihydroxyvitamin D3 in patients with type 2 diabetes.
Inaba M; Nishizawa Y; Mita K; Kumeda Y; Emoto M; Kawagishi T; Ishimura E; Nakatsuka K; Shioi A; Morii H
Osteoporos Int; 1999; 9(6):525-31. PubMed ID: 10624460
[TBL] [Abstract][Full Text] [Related]
2. Alterations in serum and urine parameters reflecting bone turnover in uremic patients during treatment with 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3.
Mortensen BM; Gordeladze JO; Lyngdal PT; Aarseth HP; Gautvik KM
Miner Electrolyte Metab; 1993; 19(2):78-85. PubMed ID: 8377728
[TBL] [Abstract][Full Text] [Related]
3. Procollagen type I C-terminal extension peptide in predialysis chronic renal failure.
Coen G; Mazzaferro S; Ballanti P; Bonucci E; Bondatti F; Manni M; Pasquali M; Perruzza I; Sardella D; Spurio A
Am J Nephrol; 1992; 12(4):246-51. PubMed ID: 1481872
[TBL] [Abstract][Full Text] [Related]
4. VDR gene polymorphisms are overrepresented in german patients with type 1 diabetes compared to healthy controls without effect on biochemical parameters of bone metabolism.
Fassbender WJ; Goertz B; Weismüller K; Steinhauer B; Stracke H; Auch D; Linn T; Bretzel RG
Horm Metab Res; 2002 Jun; 34(6):330-7. PubMed ID: 12173074
[TBL] [Abstract][Full Text] [Related]
5. Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology.
Kemink SA; Hermus AR; Swinkels LM; Lutterman JA; Smals AG
J Endocrinol Invest; 2000 May; 23(5):295-303. PubMed ID: 10882147
[TBL] [Abstract][Full Text] [Related]
6. Effect of short course of 1,25-dihydroxyvitamin D3 on biochemical markers of bone remodelling in postmenopausal women.
Sirtori P; Sosio C; Resmini G; Rubinacci A
Pharmacol Res; 1996 Jun; 33(6):353-9. PubMed ID: 8971958
[TBL] [Abstract][Full Text] [Related]
7. Significant inverse relationship between serum undercarboxylated osteocalcin and glycemic control in maintenance hemodialysis patients.
Okuno S; Ishimura E; Tsuboniwa N; Norimine K; Yamakawa K; Yamakawa T; Shoji S; Mori K; Nishizawa Y; Inaba M
Osteoporos Int; 2013 Feb; 24(2):605-12. PubMed ID: 22581293
[TBL] [Abstract][Full Text] [Related]
8. Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus.
Okazaki R; Miura M; Toriumi M; Taguchi M; Hirota Y; Fukumoto S; Fujita T; Tanaka K; Takeuchi A
Endocr J; 1999 Dec; 46(6):795-801. PubMed ID: 10724355
[TBL] [Abstract][Full Text] [Related]
9. Increasing serum osteocalcin after glycemic control in diabetic men.
Sayinalp S; Gedik O; Koray Z
Calcif Tissue Int; 1995 Dec; 57(6):422-5. PubMed ID: 8581873
[TBL] [Abstract][Full Text] [Related]
10. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
Lee SH; Huang TS; Hsieh SJ
Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
[TBL] [Abstract][Full Text] [Related]
11. Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis.
Lems WF; Gerrits MI; Jacobs JW; van Vugt RM; van Rijn HJ; Bijlsma JW
Ann Rheum Dis; 1996 May; 55(5):288-93. PubMed ID: 8660101
[TBL] [Abstract][Full Text] [Related]
12. The effect of intermittent slow-release sodium fluoride and continuous calcium citrate therapy on calcitropic hormones, biochemical markers of bone metabolism, and blood chemistry in postmenopausal osteoporosis.
Zerwekh JE; Padalino P; Pak CY
Calcif Tissue Int; 1997 Oct; 61(4):272-8. PubMed ID: 9312196
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of biochemical markers in patients with metabolic bone disorders.
Hoshino H; Kushida K; Takahashi M; Kawana K; Denda M; Yamazaki K; Inoue T
Endocr Res; 1998 Feb; 24(1):55-64. PubMed ID: 9553754
[TBL] [Abstract][Full Text] [Related]
14. Effects of short-term calcium depletion and repletion on biochemical markers of bone turnover in young adult women.
Akesson K; Lau KH; Johnston P; Imperio E; Baylink DJ
J Clin Endocrinol Metab; 1998 Jun; 83(6):1921-7. PubMed ID: 9626120
[TBL] [Abstract][Full Text] [Related]
15. Influence of high glucose on 1,25-dihydroxyvitamin D3-induced effect on human osteoblast-like MG-63 cells.
Inaba M; Terada M; Koyama H; Yoshida O; Ishimura E; Kawagishi T; Okuno Y; Nishizawa Y; Otani S; Morii H
J Bone Miner Res; 1995 Jul; 10(7):1050-6. PubMed ID: 7484280
[TBL] [Abstract][Full Text] [Related]
16. Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients.
Longobardi S; Di Rella F; Pivonello R; Di Somma C; Klain M; Maurelli L; Scarpa R; Colao A; Merola B; Lombardi G
J Endocrinol Invest; 1999 May; 22(5):333-9. PubMed ID: 10401706
[TBL] [Abstract][Full Text] [Related]
17. Bone turnover in rats treated with 1,25-dihydroxyvitamin D3, 25-hydroxyvitamin D3 or 24,25-dihydroxyvitamin D3.
Mortensen BM; Gautvik KM; Gordeladze JO
Biosci Rep; 1993 Feb; 13(1):27-39. PubMed ID: 8392394
[TBL] [Abstract][Full Text] [Related]
18. The clinical significance of serum osteocalcin and N-terminal propeptide of type I collagen in predialysis patients with chronic renal failure.
Tsuchida T; Ishimura E; Miki T; Matsumoto N; Naka H; Jono S; Inaba M; Nishizawa Y
Osteoporos Int; 2005 Feb; 16(2):172-9. PubMed ID: 15164161
[TBL] [Abstract][Full Text] [Related]
19. Serum osteocalcin/bone-specific alkaline phosphatase ratio is a predictor for the presence of vertebral fractures in men with type 2 diabetes.
Kanazawa I; Yamaguchi T; Yamamoto M; Yamauchi M; Yano S; Sugimoto T
Calcif Tissue Int; 2009 Sep; 85(3):228-34. PubMed ID: 19641839
[TBL] [Abstract][Full Text] [Related]
20. Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: a dose response study.
Brixen K; Kassem M; Nielsen HK; Loft AG; Flyvbjerg A; Mosekilde L
J Bone Miner Res; 1995 Dec; 10(12):1865-74. PubMed ID: 8619366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
